Altimmune board of directors appoint Jerry Durso as Chairman

Altimmune (ALT) announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board’s ongoing succession planning and aligns with the Company’s planned advancement into Phase 3 development of pemvidutide in metabolic dysfunction-associated steatohepatitis. Altimmune expects to hold an End-of-Phase 2 Meeting with the FDA for MASH in the fourth quarter of 2025.